Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

How NIH, FDA Nominees May Affect Rheumatology

From the College  |  March 11, 2025

The nominations of Jay Bhattacharya, MD, PhD, as director of the National Institutes of Health and Martin Makary, MD, MPH, for commissioner of the Food & Drug Administration have the potential to significantly impact federally funded healthcare research, federal responses to public health emergencies and federal regulation of drugs and medical devices.

Flares Rare After COVID Vaccination

Catherine Kolonko  |  March 7, 2025

The development of a vaccine for COVID-19 changed the course of the pandemic; however, it also raised questions about whether to withhold or reduce immunosuppressive therapies and other medications for patients with inflammatory, rheumatic and musculoskeletal disease (IRMD), note the authors of a new study published in Annals of the Rheumatic Diseases. An argument for…

Rheum After 5: Embracing Their Inner Swiftie

Linda Childers  |  March 7, 2025

Marked by their passionate support of Taylor Swift, several rheumatologists, rheumatology professionals and ACR staff who identify as Swifties spoke to us about their in-depth knowledge of Swift’s music and active engagement in fan discussions and events.

Global Summit Addresses Worldwide Rheumatology Workforce Challenges

Eric L. Matteson, MD, MPH, & Evelyn Hsieh, MD, PhD  |  March 7, 2025

Rheumatology workforce challenges are a global concern. Many challenges, especially the lack of trained rheumatology clinicians, are similar among countries and regions of the world, while others differ. The 2024 ACR Global Summit session on workforce featured a discussion by representatives of regional rheumatology organizations and the ACR addressing issues central to developing and retaining…

ACR Image Competition 2024 Results, Part 4

Noor Alanni, BAO, MB, MBChB  |  March 7, 2025

For the 2024 Image Competition, the ACR sought images with educational or remarkable manifestations representing a diverse range of pediatric patients with autoimmune, inflammatory, infectious and malignant drivers of rheumatic disease. Here, we showcase the winning images from the Middle East and North Africa. Lipoma Arborescens Revealed A 10-year-old boy, presented with a five-year history…

Editor's Pick

Cannabis for Pain Management in Rheumatology

Joanna Zeiger, PhD, & Kaleb Michaud, PhD  |  March 7, 2025

‘Cannabis has a long history of being used for pain management,’ says Physician Editor Bharat Kumar, MD, MME, FACP, FAAAAI, RhMSUS. ‘What does it mean for rheumatology patients moving forward? Read our article for one answer to this question.’ As cannabis becomes more widely legalized, both in the U.S. and internationally, its use for pain…

2025 Advocates for Arthritis Applications Now Open

From the College  |  March 6, 2025

This annual event, to be held May 4–6, brings together the rheumatology community to advocate on Capitol Hill for the profession and rheumatic disease patients.

Will Telehealth Make It to April? 

From the College  |  March 6, 2025

Medicare’s current telehealth flexibilities are set to expire March 31. To avoid a government shutdown, Congress must pass a  appropriations package by midnight on March 14. The ACR is preparing for the impacts if a telehealth extension does not pass.

Potential Biologic Drug Treatment for IgG4-RD Identified

Deborah Levenson  |  March 6, 2025

Inebilizumab reduces the risk of immunoglobulin G4-related disease (IgG4-RD) flares and increases the likelihood of flare-free, complete remission at one year, a recent study shows.1 The randomized, doubleblind, placebo-controlled MITIGATE trial showed that inebilizumab reduced the risk of IgG4-RD symptoms by 87%, compared with placebo. About IgG4-RD IgG4-RD is chronic, rare condition that has, so…

The Transition from a Rheumatology Fellowship to Private Practice

Tom Berry, DO  |  March 6, 2025

The transition from being a rheumatology fellow to being in private practice is significant. As I reflect on the past two years, I want to share my observations and begin a conversation about how to prepare rheumatology fellows for careers as practicing rheumatologists. The difference between learning about rheumatology and practicing rheumatology is nuanced. Upon…

  • « Previous Page
  • 1
  • …
  • 4
  • 5
  • 6
  • 7
  • 8
  • …
  • 816
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences